Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week.

[1]  B. Maron,et al.  Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. , 2019, Circulation.

[2]  B. Maron,et al.  Clinical Course and Management of Hypertrophic Cardiomyopathy , 2018, The New England journal of medicine.

[3]  Albert-László Barabási,et al.  Network-based approach to prediction and population-based validation of in silico drug repurposing , 2018, Nature Communications.

[4]  Marcel E Dinger,et al.  Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. , 2018, Journal of the American College of Cardiology.

[5]  Joseph Loscalzo,et al.  NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension , 2018, Science Translational Medicine.

[6]  Horst Olschewski,et al.  Network Analysis to Risk Stratify Patients With Exercise Intolerance , 2018, Circulation research.

[7]  Timothy LaRock,et al.  Reducing Network Incompleteness Through Online Learning : A Feasibility Study , 2018 .

[8]  Yee Lian Chew,et al.  Network control principles predict neuron function in the Caenorhabditis elegans connectome , 2017, Nature.

[9]  B. Maron,et al.  How to Image Hypertrophic Cardiomyopathy. , 2017, Circulation. Cardiovascular imaging.

[10]  T. Driscoll,et al.  Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. , 2017, Circulation. Cardiovascular genetics.

[11]  M. Link,et al.  Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. , 2017, Journal of the American College of Cardiology.

[12]  A. Bahl,et al.  ACE2, CALM3 and TNNI3K polymorphisms as potential disease modifiers in hypertrophic and dilated cardiomyopathies , 2017, Molecular and Cellular Biochemistry.

[13]  Peter Szolovits,et al.  Genetic Misdiagnoses and the Potential for Health Disparities. , 2016, The New England journal of medicine.

[14]  B. Maron,et al.  How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice. , 2016, JAMA cardiology.

[15]  P. Brink,et al.  MYBPH acts as modifier of cardiac hypertrophy in hypertrophic cardiomyopathy (HCM) patients , 2016, Human Genetics.

[16]  B. Tümmler,et al.  Origins of cystic fibrosis lung disease. , 2015, The New England journal of medicine.

[17]  B. Brundel,et al.  Animal and in silico models for the study of sarcomeric cardiomyopathies. , 2015, Cardiovascular research.

[18]  A. Barabasi,et al.  Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.

[19]  Matthew S. Lebo,et al.  Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.

[20]  D. Meyerholz,et al.  Origins of cystic fibrosis lung disease. , 2015, The New England journal of medicine.

[21]  E. Cook,et al.  Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy , 2014, Circulation.

[22]  S. Gallati.  The Application of Clinical Genetics Dovepress Disease-modifying Genes and Monogenic Disorders: Experience in Cystic Fibrosis , 2022 .

[23]  B. Maron,et al.  Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management. , 2013, The American journal of cardiology.

[24]  K. Siminovitch,et al.  Toronto Hypertrophic Cardiomyopathy Genotype Score for Prediction of a Positive Genotype in Hypertrophic Cardiomyopathy , 2013, Circulation. Cardiovascular genetics.

[25]  S. Gabriel,et al.  Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. , 2012, American journal of human genetics.

[26]  W. Manning,et al.  Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy , 2010, Circulation.

[27]  M. Ackerman,et al.  Is Genotype Clinically Useful in Predicting Prognosis in Hypertrophic Cardiomyopathy? Mutation Type Is Not Clinically Useful in Predicting Prognosis in Hypertrophic Cardiomyopathy Response by Ho on P 2450 Controversies in Cardiovascular Medicine , 2022 .

[28]  B. Byrne,et al.  Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. , 2010, Circulation.

[29]  W. Manning,et al.  Response to Letter Regarding Article, “Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy” , 2009 .

[30]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[31]  W. Rottbauer,et al.  Cardiac Myosin Light Chain-2: A Novel Essential Component of Thick-Myofilament Assembly and Contractility of the Heart , 2006, Circulation research.

[32]  Y S Morsi,et al.  Artificial Aortic Valves: An Overview , 2004, The International journal of artificial organs.

[33]  W. Roberts,et al.  Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. , 2000, Journal of the American College of Cardiology.

[34]  H. Watkins,et al.  Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[36]  W. Roberts,et al.  Relation between extent of cardiac muscle cell disorganization and left ventricular wall thickness in hypertrophic cardiomyopathy. , 1992, The American journal of cardiology.

[37]  W. Roberts,et al.  Diversity of Structural Mitral Valve Alterations in Hypertrophic Cardiomyopathy , 1992, Circulation.

[38]  S. Solomon,et al.  Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. , 1989, The New England journal of medicine.

[39]  W. Roberts,et al.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. , 1986, Journal of the American College of Cardiology.

[40]  B. Maron,et al.  Hypertrophic cardiomyopathy: a discussion of nomenclature. , 1979, The American journal of cardiology.